Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.13 Insider Own24.81% Shs Outstand125.22M Perf Week-6.96%
Market Cap138.31M Forward P/E- EPS next Y-1.32 Insider Trans-0.11% Shs Float97.19M Perf Month-25.69%
Income-141.27M PEG- EPS next Q-0.49 Inst Own65.35% Short Float / Ratio24.04% / 6.60 Perf Quarter-70.52%
Sales127.24M P/S1.09 EPS this Y57.39% Inst Trans15.85% Short Interest23.37M Perf Half Y-78.03%
Book/sh-0.12 P/B- EPS next Y-33.94% ROA-41.58% Target Price9.25 Perf Year-83.54%
Cash/sh1.31 P/C0.81 EPS next 5Y- ROE-538.57% 52W Range0.91 - 7.17 Perf YTD-80.89%
Dividend- P/FCF- EPS past 5Y-0.93% ROI-74.01% 52W High-85.08% Beta2.49
Dividend %- Quick Ratio2.47 Sales past 5Y49.53% Gross Margin88.72% 52W Low17.58% ATR0.17
Employees431 Current Ratio2.71 Sales Q/Q-91.00% Oper. Margin-102.89% RSI (14)42.44 Volatility9.91% 20.03%
OptionableYes Debt/Eq- EPS Q/Q23.83% Profit Margin-111.03% Rel Volume0.77 Prev Close1.04
ShortableYes LT Debt/Eq- EarningsNov 02 BMO Payout- Avg Volume3.54M Price1.07
Recom1.86 SMA20-4.81% SMA50-30.53% SMA200-73.60% Volume2,733,374 Change2.88%
Date Action Analyst Rating Change Price Target Change
Jun-26-23Resumed Oppenheimer Outperform $12
Apr-21-23Initiated JP Morgan Neutral $7
Jul-23-21Downgrade Goldman Neutral → Sell $24 → $7
May-18-21Resumed Goldman Neutral $24
Mar-05-21Upgrade Chardan Capital Markets Neutral → Buy $30
Sep-18-20Downgrade Chardan Capital Markets Buy → Neutral $32.50 → $27.50
Aug-18-20Initiated Piper Sandler Overweight $40
Aug-11-20Upgrade Jefferies Hold → Buy $4 → $29
Aug-11-20Reiterated H.C. Wainwright Buy $8 → $41
Apr-30-19Initiated Jefferies Hold $7
Nov-28-23 09:18AM
Nov-27-23 07:01PM
Nov-21-23 06:00AM
Nov-05-23 02:22PM
Nov-02-23 08:47AM
07:32AM Loading…
Nov-01-23 10:30AM
Oct-30-23 05:30PM
Oct-19-23 10:30AM
Oct-12-23 07:00AM
Oct-06-23 07:00AM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
07:00AM Loading…
Sep-08-23 07:00AM
Sep-07-23 10:00AM
Aug-29-23 09:00AM
Aug-09-23 06:27AM
Aug-08-23 08:25AM
Aug-04-23 07:00AM
Aug-01-23 07:00AM
Jul-14-23 04:01PM
Jul-07-23 10:17AM
Jun-21-23 09:00AM
Jun-17-23 03:45PM
Jun-09-23 07:00AM
07:00AM Loading…
Jun-05-23 07:00AM
Jun-02-23 07:00AM
May-30-23 04:00PM
May-16-23 06:00AM
May-10-23 07:00AM
May-09-23 08:15AM
May-08-23 07:00AM
May-05-23 07:00AM
Apr-29-23 09:03AM
Apr-27-23 10:03AM
Apr-26-23 07:46PM
Apr-24-23 02:09AM
Apr-20-23 09:45AM
Apr-14-23 05:10AM
Apr-07-23 07:00AM
Apr-04-23 04:30PM
Mar-22-23 03:44AM
Mar-09-23 07:00AM
Mar-08-23 10:45PM
Mar-07-23 10:28PM
Mar-03-23 04:00PM
Feb-28-23 07:00AM
Feb-27-23 07:00AM
Feb-14-23 07:00AM
Feb-08-23 07:28AM
Feb-03-23 11:30AM
Jan-28-23 07:51AM
Jan-13-23 07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Nov-22-22 04:01PM
Nov-08-22 05:35AM
Nov-02-22 08:35AM
Oct-27-22 07:00AM
Oct-26-22 07:00AM
Oct-23-22 03:30PM
Oct-19-22 02:00PM
Oct-12-22 07:00AM
Sep-22-22 05:51AM
Sep-08-22 07:00AM
Sep-07-22 07:00AM
Aug-29-22 06:43AM
Aug-08-22 06:11AM
Aug-04-22 07:00AM
Aug-03-22 08:15AM
Jul-28-22 07:00AM
Jul-19-22 12:21PM
Jun-30-22 07:30AM
Jun-19-22 10:47AM
Jun-07-22 12:18PM
Jun-01-22 07:00AM
May-23-22 08:00AM
May-22-22 03:15PM
May-10-22 07:00AM
May-05-22 09:30AM
May-04-22 08:25AM
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shaff Eric D.CEO and PresidentOct 30Sale1.358,55211,545115,620Oct 31 09:40 PM
von Moltke LisaSee RemarksOct 30Sale1.354,2325,7139,513Oct 31 09:36 PM
DesRosier ThomasChief Legal Officer and EVPOct 30Sale1.354,1565,611113,891Oct 31 09:39 PM
Arkowitz DavidChief Financial OfficerOct 30Sale1.354,0665,489175,756Oct 31 09:39 PM
Ege David S.See RemarksOct 30Sale1.354,0665,48966,991Oct 31 09:39 PM
Henn Matthew R.See RemarksOct 30Sale1.353,8865,24656,356Oct 31 09:36 PM
Young Teresa L.See RemarksOct 30Sale1.352,9073,9248,454Oct 31 09:40 PM
Cloghessy PaulaSee RemarksOct 30Sale1.352,9043,92045,684Oct 31 09:43 PM
Cloghessy PaulaSee RemarksOct 27Option Exercise0.009,418048,588Oct 31 09:43 PM
Young Teresa L.See RemarksOct 27Option Exercise0.0011,361011,361Oct 31 09:40 PM
Shaff Eric D.CEO and PresidentOct 27Option Exercise0.0027,8380124,172Oct 31 09:40 PM
Arkowitz DavidChief Financial OfficerOct 27Option Exercise0.0013,2090179,822Oct 31 09:39 PM
Ege David S.See RemarksOct 27Option Exercise0.0011,361071,057Oct 31 09:39 PM
DesRosier ThomasChief Legal Officer and EVPOct 27Option Exercise0.0013,5010118,047Oct 31 09:39 PM
Henn Matthew R.See RemarksOct 27Option Exercise0.0012,623060,242Oct 31 09:36 PM
von Moltke LisaSee RemarksOct 27Option Exercise0.0013,745013,745Oct 31 09:36 PM
Ege David S.See RemarksApr 28Sale5.197,03836,52759,696May 01 04:46 PM